Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer

SIMPLE SUMMARY: In randomized trials, both chemotherapy and androgen-receptor signaling inhibitors provided significant survival benefits in patients with metastatic prostate cancer (mPCa). However, it is largely unknown to what extent these therapeutic advances have impacted the general, real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattrini, Carlo, Soldato, Davide, Rubagotti, Alessandra, Zinoli, Linda, Zanardi, Elisa, Barboro, Paola, Messina, Carlo, Castro, Elena, Olmos, David, Boccardo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650780/
https://www.ncbi.nlm.nih.gov/pubmed/33022939
http://dx.doi.org/10.3390/cancers12102855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650780/
https://www.ncbi.nlm.nih.gov/pubmed/33022939
http://dx.doi.org/10.3390/cancers12102855

Ejemplares similares